EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 7 May 2026

Why cardiovascular health checks: The case for EU action

Learn more here.

Cardiovascular diseases (CVDs) account for approximately 1.7 million deaths each year, affect around 62 million people, and generate economic costs exceeding EUR 282 billion annually. Early detection and prevention should be viewed as long term investments in health system sustainability.

To effectively address this pressing burden, in December 2025 the European Commission launched the EU Safe Hearts Plan. The proposal for a Council Recommendation on health checks is a core component of the Safe Hearts Plan.

This is a golden opportunity to step up early detection, improve outcomes across the EU, and save costs for health systems and societies.

ONE Vision: a "North Star" for a future-ready regulatory system

Europe’s regulatory system for medicines is one of the most scientifically rigorous and respected in the world. As science advances and new types of therapies emerge, ensuring the system continues to evolve will be key to bringing innovation to European patients faster.

In a new article published by Pink Sheet / Citeline, EFPIA outlines ONE Vision – a proposal for a future-ready regulatory framework.

Read the full article here.

Events

Unlocking Europe’s Life Science potential: A policy agenda for competitiveness, innovation...
08 May 2026 (The Landmark Nicosia, Cyprus)

Europe stands at a critical moment for its life sciences sector. Across the world, governments are actively strengthening... Read more

EFGCP Conference 2026
12 May 2026 (Brussels, Hybrid)

Join the EFGCP Conference 2026 in Brussels to explore how ethical review systems can strengthen Europe’s clinical research... Read more

European Pharmaceutical Law Forum
19 May 2026 (Brussels, Belgium)

The European pharmaceutical market is facing a moment of profound change. With sweeping updates to the EU pharmaceutical... Read more

European Conference on Rare Diseases and Orphan Products (ECRD) 2026
03 June 2026 (Prague & Online)

The next ECRD will be held on 3 & 4 June 2026 in Prague and will be titled “Rare Diseases in a Changing & Competitive... Read more

What we are reading

Could the EU use public health data to follow the US single-trial policy?
On 06 May 2026 (Pink Sheet )

Data gathered through the European Health Data Space initiative could reduce the number of clinical trials required... Read more

Government renews call to Europe for pharmaceutical taskforce
On 05 May 2026 (RTE)

The Government has renewed its call on the European Commission to set up a pharmaceutical taskforce in light of ongoing... Read more

Brussels pushes to wrap up ‘last’ health files as biotech gap looms
On 05 May 2026 (Euractiv)

Commission says next two presidencies will be key to progress.

Faster Dutch research system needed to stop clinical trial decline
On 30 April 2026 (Euractiv)

Clinical trials in the Netherlands have been declining for years, experts say the main issue isn’t scientific quality... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu